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ABSTRACT

Introduction.

Accurate assessment of prognosis is a key driver of clinical decision making

in congenital heart disease (CHD), but is complicated because CHD represents such a diverse
collection of conditions. The aim of this investigation is to derive, validate, and calibrate
multivariable predictive models for time to surgical or catheter-mediated intervention (INT) in
CHD and for time to death in CHD. Methods. 4108 unique subjects were prospectively and
consecutively enrolled, and randomized to derivation and validation cohorts. Total follow up was
26,578 patient-years, with 102 deaths and 868 INTs. Accelerated failure time multivariable
predictive models for the outcomes, based on primary and secondary diagnoses,
pathophysiologic severity, age, gender, genetic comorbidities, and prior interventional history,
were derived using piecewise exponential methodology. The model predictions were validated,
calibrated, and evaluated for sensitivity to changes in the independent variables. Results. Model
validity was excellent for prediction of both mortality and INT at 4 months, 1 year, 5 years, 10
years, and 22 years (areas under receiver operating characteristic curves ranged from 0.809 to
0.919), and predictions calibrated well with observed outcomes. Although age, gender,
secondary diagnoses, and genetic comorbidities were significant independent contributors to the
survival and/or freedom from intervention models, predicted outcomes were most sensitive to
variations in a composite predictor incorporating primary diagnosis, pathophysiologic severity,
and history of prior intervention. An active cohort effect is identified in which predicted
mortality and intervention both increased throughout the 22 years of study. Conclusions. Time
to INT and time to death in CHD can be predicted with accuracy based on clinical variables.
The objective predictions available through these models could educate both patient and
provider, and inform clinical decision making in CHD.

INTRODUCTION.
Accurate assessment of prognosis is one of the key drivers of clinical decision making.
Knowledge of prognosis in congenital heart disease (CHD) is especially complicated because it
represents such a diverse collection of conditions. Although some determinants of outcome are
known for individual lesions, the degree to which these determinants are shared across specific
CHD diagnoses and the ways they interact within and across diagnosis groups remain largely
unknown. It is well established that CHD outcomes depend on the specific primary cardiac
lesion(1-3), its pathophysiologic severity(4-6), history of prior cardiovascular intervention(5,6),
genetic comorbidities such as Down Syndrome(7,8), large chromosome trisomies(9) and other
inborn disorders(10,11), and even gender(12,13). Moreover, general improvements in CHD care
have changed outcomes over the years. Therefore, due to a substantial cohort effect, prognosis
can depend on the era during which the observations are made(14-16). Successful surgical or
catheter-mediated interventions have, in recent years, become more common and mortality rates
have fallen(17), leading many to contend that simple survival analysis no longer conveys a full
and useful picture of CHD prognosis(17,18). Accordingly, both mortality and need for intervention
are relevant outcomes for patients with CHD.
Piecewise parametric modelling of time related outcomes is increasingly applied for
predictions in medicine in areas such as organ transplant(19,20), oncology(21), neuropsychiatric
disorders(22,23), and success or failure of therapies as diverse as antibiotics and
contraceptives(24,25). We are aware of no prior application of this method in CHD. There has,
however, been great interest in long-term natural history of individual forms of CHD(26,27), and
especially about outcomes after specific surgical or catheter-mediated interventions(3, 16, 28-30).
Although factors associated with survival and/or freedom from intervention are commonly

identified using Kaplan-Meier curves or proportional hazards modeling, general predictive
models are not usually subjected to formal independent validation. Identification of factors
associated with acute mortality of surgical intervention in CHD have received considerable
attention, and there is ample evidence that the RACHS-I stratification scheme, a consensus-based
risk adjustment(31) is predictive of in-hospital post-surgical mortality(32,33), other scoring
strategies have proven less reliable(34). A model for acute risk surrounding non-cardiac
procedures in patients with CHD has been validated(35). Although there is some evidence that the
more severe strata of RACHS-I are associated with greater ongoing risks for death and reintervention(36), it is not necessarily clear, that the presumption that risk factors for acute
outcome can optimally describe risks in longer term. Among adults with CHD, it has been
useful to repurpose a predictive model originally derived for heart failure to identify those at risk
for poor outcome in general(37). Others have derived promising but unvalidated models in an
adult CHD population which identify associations of primary diagnosis, interventional history,
and disease severity with mortality over time(38,39). In another unvalidated model of 15-year
survival for CHD diagnosed in infancy, mortality risk was independently associated with
prematurity, primary and secondary cardiac diagnoses, gender, and noncardiac malformations(40).
A general model to predict individual outcomes within the diverse CHD population has yet to
be developed. If a reliable model of this sort were constructed, it is expected that prognostic
information available from it would be valuable for patients, their families, and their physicians.
The aim of this investigation is to derive, validate, and calibrate multivariable predictive models
for time to surgical or catheter-mediated intervention in CHD and for time to death in CHD.

METHODS

Clinical Material. Beginning June 18, 1998 and concluding June 30, 2020, 4108 unique
subjects were prospectively and consecutively enrolled. Inclusion criteria were: (1) an encounter
with a single identified practitioner of pediatric cardiology in an outpatient clinic for young
people with heart disease, working in the larger context of an academic group practice of
pediatric cardiology; and (2) the presence of a major or minor anatomic or hemodynamic
cardiovascular lesion. There were no specific exclusion criteria. Using a random number table,
the subjects were randomized to a derivation cohort, representing 80% of the patients, and a
validation cohort, representing 20%. This research was approved by the Institutional Review
Board for University of Nebraska Medical Center and Children’s Hospital and Medical Center
(Omaha).

Data collected. At enrollment, the following information was recorded: age, enrollment date,
gender, and presence or absence of: (1) trisomy 21; (2) other constellation of deformities,
chromosomal abnormality, or inborn error of metabolism; (3) secondary cardiac defect(s); and
(4) prior cardiovascular surgical or catheter mediated interventions. The primary cardiovascular
diagnosis was recorded. When more than one diagnosis was present, the primary diagnosis was
identified as the highest ranked diagnosis based on a previously-described empiric semi severitybased diagnoses hierarchy6. All other cardiovascular diagnoses were recorded, and denoted as
secondary. Based on a previously described pathophysiologic severity score for hemodynamic
burden6, the degree of left ventricular volume and pressure overload, right ventricular volume
and pressure overload, cyanosis, and systemic ventricular dysfunction were graded as none, mild,
moderate, or severe. Chart review identified the times at which two outcomes occurred: (1) death
and (2) invasive cardiovascular intervention (surgical or catheter mediated).

Statistical methods.
Descriptive. Central tendencies and spread of continuous variables were described with
means and standard deviations. Categorical variables were described with counts and
proportions. The two time-dependent outcomes were summarized using the Kaplan-Meier
method.
Combining context-dependent predictive variables. Anticipating that the associations
of the six pathophysiologic severity variables, diagnosis, and prior intervention to outcome
would be complex, and vary widely depending on the combinations in which they exist, the
derivation cohort was inspected to see which of these combinations contained 25 or more
examples. Twenty-five was chosen based on a two-tailed power calculation which demonstrated
that this number would be required for a comparison of Kaplan-Meier curves which would
assure detection of Hazard Ratio>1.75, relative to the remaining members of the derivation
cohort, given a reference hazard = 0.4, =0.05, and power 0.801. Subjects within these groups
were assigned a group-specific score based on proportion deceased at 10 years, and this was
denoted DPPIm (Diagnosis, Pathophysiology, Prior Intervention, mortality). An analogous
procedure yielded scores for intervention DPPIi. For groups represented by fewer than 25
members, and therefore insufficient for confident direct estimation of DPPIi from product-limit
estimation, a three-stage process allowed imputation of DPPIi. (1) Using the entire derivation
cohort, product-limit estimation provided one approximation of probability of intervention based
solely on diagnosis and interventional status (ignoring pathophysiology) or “dpi-based-DPPIi”,
and another based solely on pathophysiology (ignoring diagnosis and interventional status) or pbased-DPPIi. (2) Based on the 48 DPPI categories for which DPPIi is known, a multiple linear
regression was calculated to predict DPPIi from dpi-based-DPPIi, p-based-DPPIi, and their

product. (3) The regression equation was applied to the uncommon categories with small n to
estimate DPPIi, and when that estimate exceeded 1.0, a value of 1.0 was applied. An analogous
process was applied to estimate DPPIm for members of unusual combination groups (See
Appendix).
Scores for secondary diagnosis relative to mortality (SECDm), and for secondary diagnosis
relative to intervention (SECDi) were obtained from 13 categories of secondary cardiac
diagnoses, again using 10 year outcomes from Kaplan-Meier curves.
Derivation of predictive models. Parametric survival models were sought for the two
time-dependent outcomes of interest, but in the derivation cohort, accelerated failure time
assumptions were not fulfilled for exponential models evaluated over the full follow-up duration.
Therefore, death rates and intervention rates after enrollment were estimated using piecewise
exponential models, stratified using the following intervals: 0 to 4 months, 4 months to 1 year, 1
to 5 years, 5 to 10 years, and 10 to 22 years. Goodness of fit within each segment of the model
were tested by plotting the negative log of the survival (or freedom from intervention) against
time, and confirming a near linear association. Independent variables from which the freedom
from intervention model was built include DPPIi, SECDi, age, gender, date of entry into study,
Down syndrome, and other inborn or genetic syndrome. Each segment of the piecewise model
was generated by backward selection, with criterion for retention  = 0.15. In an analogous
fashion the survival model was built starting with independent variables DPPIm, SECDm, age,
gender, date of entry into study, Down syndrome, and other inborn or genetic syndrome.
Validation, calibration, and sensitivity analysis of predictive models. Models were
validated using a randomly selected 20% of cases which had not been used to derive the model.
Receiver operating characteristic (ROC) curves were generated for the survival and freedom

from intervention models at 4 months, 1, 5, 10, and 22 years by plotting sensitivity against 1
minus the specificity of model predictions across the spectrum of predicted outcomes. Areas
under the ROC curves were determined and these were reported as a measure of model validity,
where 1.0 represents perfect discrimination, 0.7-0.8 acceptable, 0.8-0.9 excellent, and >0.9
outstanding. Survival and freedom from intervention model calibration was evaluated at 4
months, 1, 5, 10, and 22 years in 2 ways. First, Spiegelhalter Z score was calculated, with
significance criterion p>0.05 suggesting satisfactory calibration. Second, the validation cohort
was empirically stratified by predicted outcome at 22 years (threshold probabilities to separate
the bins of predicted probability of freedom from cardiovascular intervention: 0.05, 0.20, 0.50,
0.90, and 0.99, and for predicted probability of survival: 0.71, 0.85, 0.90, 0.95, and 0.99), and
Kaplan-Meier curves were inspected to obtain observed outcome at 4 months, 1, 5, 10, and 22
years. At each of these timepoints, using data derived from the 6 bins of predicted probabilities,
simple linear regression was applied to predict mean observed outcome from mean predicted
outcome. These regressions were inspected for slope, intercept, and r2, to assess model
calibration. One-way sensitivity analysis was performed by plotting the variations observed in
model output when independent variables were allowed to vary over their ranges. All analyses
were performed using SAS 9.4 software (SAS Institute Inc, Cary, NC).

RESULTS
Characteristics of the derivation and validation cohorts. There were 4108 patients
included, 3285 in the derivation cohort, and 823 in the validation cohort. The independent
variable distributions and the outcomes were comparable between cohorts, and are summarized
in Table I. Total follow up time for the entire set of patients was 26,578 patient-years during
which there were 102 deaths and 868 invasive cardiovascular interventions. The distribution of
primary and secondary diagnoses was similar between the cohorts and appears representative of
the broad spectrum of cardiac diagnoses expected in a population of outpatients in a pediatric
cardiology clinic (see Tables II and III, respectively). The time-related occurrence of cardiac
intervention and death were indistinguishable between the derivation and validation cohorts
(Figure 1).

Assembly of compound predictors and assignment of values. Prior to derivation of
predictive models, combinations of primary diagnosis, pathophysiologic severity, and prior
interventional status (DPPI) were assembled and their observed associations with 10 year
outcomes were tabulated for the 48 combinations which represented 25 or more cases in the
derivation cohort. These values, derived from Kaplan-Meier estimates of probability of
intervention and probability of mortality at 10 years were noted as DPPIi and DPPIm scores,
respectively. For all other rarer combinations of diagnosis, pathophysiology, and prior
interventional history, regardless of how uncommonly they might be expected to occur, DPPIi
and DPPIm were imputed (imputation rules in Appendix), allowing the completion of
comprehensive tables of DPPIi and DPPIm (Tables IV and V, Appendix). There were 13 single
or multiple combinations of secondary diagnoses from which intervention and mortality scores

(SECDi and SECDm, respectively) were derived, and are shown in Table VI in the appendix.
Because the 13 secondary diagnosis categories were all-inclusive, no imputed value were
required.
In the derivation cohort, goodness of fit for the accelerated failure time assumption for the
piecewise exponential model was confirmed by establishing linearity of the negative log of
survival versus time within intervals: 0 to 4 months, 4 months to 1 year, 1 to 5 years, 5 to 10
years, and 10 to 22 years. Potential predictors were age, time of entry into the study, gender,
Down syndrome, and other inborn or genetic syndrome, and (for freedom from intervention
model only) DPPIi, SECDi, or (for survival model only) DPPIm, SECDm. Models for time free
from cardiovascular intervention, and survival time were generated by backward selection from
the models initially including all potential predictors ( to retain = 0.15) are summarized below:
Piecewise Model Equations
(1) (PFFI0.33= e^(0.33*e^(-(- B0 + (B1*X1) + (B2*X2) + (B3*X3) . . .+ (Bj*Xj))))
(2) (PFFI1= PFFI0.33*e^(0.67*e^(-(- B0 + (B1*X1) + (B2*X2) + (B3*X3) . . .+ (Bj*Xj))))
(3) (PFFI5= PFFI1*e^(4*e^(-(- B0 + (B1*X1) + (B2*X2) + (B3*X3) . . .+ (Bj*Xj))))
(4) (PFFI10= PFFI5*e^(5*e^(-(- B0 + (B1*X1) + (B2*X2) + (B3*X3) . . .+ (Bj*Xj))))
(5) (PFFI22= PFFI10*e^(12*e^(-(- B0 + (B1*X1) + (B2*X2) + (B3*X3) . . .+ (Bj*Xj))))
(6) (PSURV0.33= e^(0.33*e^(-(- B0 + (B1*X1) + (B2*X2) + (B3*X3) . . .+ (Bj*Xj))))
(7) (PSURV1= PSURV0.33*e^(0.67*e^(-(- B0 + (B1*X1) + (B2*X2) + (B3*X3) . . .+ (Bj*Xj))))
(8) (PSURV5= PSURV1*e^(4*e^(-(- B0 + (B1*X1) + (B2*X2) + (B3*X3) . . .+ (Bj*Xj))))
(9) (PSURV10= PSURV5*e^(5*e^(-(- B0 + (B1*X1) + (B2*X2) + (B3*X3) . . .+ (Bj*Xj))))
(10) (PSURV22= PSURV10*e^(12*e^(-(- B0 + (B1*X1) + (B2*X2) + (B3*X3) . . .+ (Bj*Xj))))
Where PFFIt and PSURVt = model predictions for probability of freedom from intervention and
probability of survival at time t, respectively. Values for B and X are given in the table below.

Eqn

Risk* B0

B1
X1

B2
X2

(1)

High

-2.10

0.065
Age**

Low

-53.89

High

-1.61

4.24
DPPIi
60.43
DPPIi
4.59
DPPIi

0.054
Age

-0.23
Male

Low

6.73

High

-0.92

-0.018
EntryT^

-34.70

High

-1.04

0.40
Age

-0.23
Male

Low

-40.01

High

-0.15

-0.22
Male

-0.054
EntryT

Low

-37.39

High

-1.89

0.052
Age
11.58
SECi
0.67
SECi
13.92
SECi
0.029
Age
-0.075
Age
0.098
EntryT

-0.29
Male

Low

Low

-260.77

High

-6.18

Low

7.02

High

-15.80

Low

7.94

High

-0.60

Low

-145.78

High

-4.29

5.14
DPPIi
32.29
DPPIi
5.09
DPPIi
36.99
DPPIi
5.03
DPPIi
46.23
DPPIi
4.93
DPPIm
269.58
DPPIm
12.15
DPPIm
-3.28
OtherIG
11.20
DPPIm
-3.04
OtherIG
8.01
DPPIm
154.85
DPPIm
11.01
SECm

Low

8.63

(2)

(3)

(4)

(5)

(6)

(7)

(8)

(9)

(10)

B3
X3

B4
X4

B5
X5

-0.033
EntryT

-2.3859
Downs

11.06
SECm

-0.047
Age
-0.083
Age
-0.060
Age

-2.34
OtherIG^^

-1.00
Male

-1.52
OtherIG

DPPIi= Diagnosis Pathophysiology Prior Intervention based Intervention Score.
DPPIm = Diagnosis Pathophysiology Prior Intervention based Mortality Score.
SECDi = Secondary Diagnosis based Intervention Score.
SECDm = Secondary Diagnosis based Mortality Score.
*Due to DPPI-dependent variations in the associations of DPPI with outcome, high- and low-risk
arms of the models were derived. Intervention Risk is high when DPPIi <0.93, and high risk

intervention model is applied, otherwise low risk model is used. Mortality Risk is high when
DPPIm <0.98, and high risk mortality model is applied, otherwise low risk model is used
**Age = age in years
^Entry time if time in years since onset of investigation (June, 1998)
^^otherIG = Other inborn or genetic condition

Calculation of the areas under the receiver operating characteristic (ROC) curves for
prediction of actual freedom from cardiovascular intervention in the validation cohort using the
PFFI (predicted freedom from intervention) model revealed values 0.893-0.919 throughout the
follow-up timeframe, demonstrating the model to be highly valid (Figure 2). PFFI demonstrated
a linear relationship between predicted and observed values at each follow-up interval (4 months
– 22 years), with slope approximately 1 and intercept close to 0, confirming a well calibrated
predictive model. PSURV (predicted survival) was a valid model for prediction of survival
across the spectrum of follow-up intervals, as demonstrated by areas under the ROC curve 0.8090.919 (Figure 3). Significant linear relationships between observed and expected survival were
identified at all follow-up intervals, but calibration was considerably best at 5 and 10 years
follow-up (high R2, and linear relation more closely approximating slope of 1 and intercept of 0)
than it was at other follow-up intervals.
As expected, predictions of both survival and freedom from intervention were more sensitive
to changes in DPPI score than to other predictive variables (Figure 4). Secondary diagnosis
score influenced survival more than freedom from intervention. Predicted outcomes varied only
minimally with gender (females had slightly more favorable prognosis) and Down syndrome
(poorer survival, but no difference in freedom from intervention). Other genetic syndromes
demonstrated substantial association with poorer survival, but not with freedom from
intervention. Although the effects were relatively small, PSURV was lower, and PFFI was

higher with increasing age. Predicted survival and freedom from intervention were both lower as
the study progressed, confirming a cohort effect for both outcomes.

DISCUSSION

Summary of Main Findings. This report describes the derivation and validation of a general
predictive model for outcomes in outpatients with CHD based on a large number of subjects
observed prospectively for up to 22 years. This model for prediction of survival and freedom
from invasive cardiovascular intervention demonstrates excellent validity, and performs well on
a clinical sample comprised of CHD outpatients independent of those from which the model was
derived. As expected, by far the greatest influence is a combination of primary diagnosis, history
of prior intervention, and the nature and severity of pathophysiologic abnormalities. Factors
such as age of the patient, gender, secondary cardiac diagnoses, and comorbid genetic conditions
are minor contributors to predicted outcomes. Reflecting a practice pattern in which intervention
for CHD is generally offered to patients regardless of genetic comorbidities, the model shows
that predicted probability of intervention did not vary with these factors, even though predicted
mortality did. An active cohort effect is identified in which predicted mortality and intervention
both increased throughout the 22 years of study. This is consistent with the expectation that
there has been a more aggressive interventional approach to CHD management in recent years.
Higher predicted mortality as years passed during this investigation does run contrary to the
notion that modern CHD outcomes ought to be better than historical. It is, however, consistent
with the concept that more aggressive care is now associated with lower hospital mortality for
severe CHD, resulting in greater numbers of fragile short-term survivors entering the outpatient
setting for ongoing care.

A novel feature of model derivation was to reduce the thousands of

possible combinations of diagnosis, history, and pathophysiology into highly predictive
continuous scores for risk of mortality and intervention for incorporation in the model.

Important interactions among diagnosis, interventional history, and pathophysiologic severity
were thereby accounted for, without introducing a grand multiplicity of interactive predictive
terms in the model and without the opacity that would result from using a neural network with
unsupervised machine learning to account for them. Moreover, outcome similarities shared
across diagnoses and pathophysiologies were successfully incorporated into the model by
imputing scores for uncommon combinations.
Potential Applications. Based on simple observations of diagnosis, pathophysiologic severity,
prior interventional history, age, gender, genetic comorbidities, and time of entry into the study,
the model reported here allows prediction of mortality and need for invasive cardiovascular
intervention in outpatients with CHD. Such predictions are potentially of considerable value to
frame in quantitative terms expectations for patients with CHD and their families. Specialists in
CHD, too, may benefit from an objective means for assessing prognosis, especially when
considering intervention for their patients. Should a specialist recommend an intervention when
the model predicts minimal probability of mortality or intervention, this should prompt careful
consideration of what special circumstances warrant the intervention in that patient at this time.
More commonly, we expect that model projections will be concordant with expertise of the
specialist, and valuable reassurance regarding the management decision would result from its
use. Expertise about prognosis across the spectrum of clinical CHD is uncommon in the broader
medical community. Generalists who only occasionally treat patients with CHD may benefit
from the cardiovascular prognostic context the model provides. There is also potential
educational value for medical trainees for whom the model can provide expectations of how
serious a threat is posed by CHD and what factors contribute to the magnitude of that threat.

This rational basis underlying decisions for cardiovascular intervention might, with the insights
provided by the model, be more transparent for learners.

Limitations. The model reported here is highly complex, so hand calculation for prediction of
outcome for an individual patient is impractical. It would, however be easily automated within a
computer application based on equations which comprise the model, thereby allowing simple
translation to the clinical setting. The model was derived and validated on the experience with
outpatients from a single general pediatric cardiology practice, and so may not generalize to
predictions for CHD inpatients or match precisely the experience in other programs and settings.
With greater differences in patient characteristics and program practices from the source, greater
caution should be exercised as the model is applied. Changes in predicted outcome will probably
continue to depend on the era during which patients come under observation, but it cannot be
concluded that the cohort effects observed in this investigation will remain stable in perpetuity.
Because of this moving target of predicted outcome, model updates will likely be necessary in
the future.

Future Directions. Recommendations for intervals of outpatient follow-up in CHD tend not to
be data driven, but are generally derived from consensus of expert opinion(41). Outcome
predictions and recommended follow-up intervals likely correlate, although it is not yet known
how strong these associations are. We recognize that prognosis for intervention and mortality is
not the only basis for follow-up recommendations, however when outcome predictions are
inconsistent with the recommendation, the guidance may merit further consideration. Patients’

expectations need to be different when definitive surgery or catheter-mediated treatment for
CHD is offered with the likelihood that of a durable good outcome from a single intervention
than they would be when serial interventions are necessary. Therefore, there is potential interest,
specifically among patients and their families, in the prediction of freedom from second
intervention. We plan to use the approach reported here to derive and validate a predictive
model for freedom from second intervention. Clinicians tend to think about prognosis as it
applies to an individual diagnosis, however many specific conditions in CHD are so rare(42-44)
that it is likely even large scale collaborative outcome studies cannot identify with confidence the
variables which affect prognosis. Model based predictions might be a satisfactory surrogate for
actual outcomes in such conditions, producing estimates for prognosis and accounting for the
factors that influence them.

Conclusion. A piecewise exponential model predicting survival and freedom from invasive
cardiovascular intervention has been derived which demonstrates excellent validity, and
performs well on a clinical sample comprised of CHD outpatients.

Table I.

Clinical Feature
Left Ventricular Volume Overload

Left Ventricular Pressure Overload

Right Ventricular Volume Overload

Right Ventricular Pressure Overload

Cyanosis

Systemic Ventricular Dysfunction

Gender
Down Syndrome
Other Genetic Syndrome
Secondary Cardiac Diagnosis
Prior Cardiac Intervention
Age at Enrollment (years; mean+SD)
Study Entry Date (years; mean+SD)
Death
Intervention
Time followed (years; mean+SD)

None
Mild
Moderate
Severe
None
Mild
Moderate
Severe
None
Mild
Moderate
Severe
None
Mild
Moderate
Severe
None
Mild
Moderate
Severe
None
Mild
Moderate
Severe
Male
Female
Present
Absent
Present
Absent
Present
Absent
Yes
No

Yes
No
Yes
No

Cohort
Derivation Validation

Total

1748 (53.2%)
1202 (36.6%)
293 (8.9%)
42 (1.3%)
2854 (86.9%)
389 (11.8%)
38 (1.1%)
4 (0.1%)
2594 (78.9%)
393 (12.0%)
249 (7.6%)
49 (1.5%)
2611 (79.5%)
399 (12.2%)
98 (3.0%)
177 (5.4%)
3151 (95.9%)
55 (1.7%)
52 (1.6%)
27 (0.8%)
3203 (97.5%)
56 (1.7%)
22 (0.7%)
4 (0.1%)
1714 (52.2%)
1571 (47.8%)
189 (5.8%)
3096 (94.2%)
274 (8.3%)
3011 (91.7%)
836 (25.5%)
2448 (74.5%)
818 (24.9%)
2466 (75.1%)
6.30+7.23
8.68+8.46
82 (2.5%)
3203 (97.5%)
683 (20.8%)
2602 (79.2%)
6.52+6.96

2204 (53.7%)
1483 (36.1%)
365 (8.9%)
56 (1.4%)
3571 (86.9%)
483 (11.8%)
49 (1.2%)
5 (0.1%)
3247 (79.0%)
490 (11.9%)
306 (7.4%)
65 (1.6%)
3251 (79.1%)
496 (12.1%)
130 (3.2%)
231 (5.6%)
3924 (95.5%)
73 (1.8%)
71 (1.7%)
40 (1.0%)
4009 (97.6%)
70 (1.7%)
25 (0.6%)
4 (0.1%)
2138 (52.0%)
1970 (48.0%)
242 (5.9%)
3866 (94.1%)
342 (8.3%)
3766 (91.7%)
1030 (25.1%)
3077 (74.9%)
1021 (24.9%)
3086 (75.1%)
6.18+7.16
8.70+6.31
102 (2.5%)
4006 (97.5%)
868 (21.1%)
3240 (78.9%)
6.47+6.93

456 (55.4%)
281 (34.4%)
72 (8.8%)
14 (1.7%)
717 (87.1%)
94 (11.4%)
11 (1.3%)
1 (0.1%)
653 (79.3%)
97 (11.8%)
57 (6.9%)
16 (1.9%)
640 (77.8%)
97 (11.8%)
32 (3.9%)
54 (6.6%)
773 (93.9%)
18 (2.2%)
19 (2.3%)
13 (1.6%)
806 (97.9%)
14 (1.7%)
3 (0.4%)
0 (0%)
424 (51.5%)
399 (48.5%)
53 (6.4%)
770 (93.6%)
68 (8.3%)
755 (91.7%)
194 (23.6%)
629 (76.4%)
203 (24.7%)
620 (75.3%)
5.74+6.84
8.77+6.21
20 (2.4%)
803 (97.6%)
185 (22.5%)
638 (77.5%)
6.28+6.83

p*
0.4634

0.9635

0.7389

0.3043

0.0678

0.5679

0.7356
0.4545
0.9419
0.2647
0.8854
0.0379
0.7318

0.9133
0.2890
0.3639

*p for differences between derivation and validation cohorts, based on chi-square for categorical
variables, and 2-tailed Student t-test for continuous variables.

Table II.
Primary Cardiac Diagnosis

Number With
Derivation Cohort Validation Cohort Total

Muscular Ventricular Septal Defect
Perimembranous Ventricular Septal Defect
Aortic Valve Disease
Pulmonary Valve Disease
Secundum Atrial Septal Defect
Aortic Coarctation
Patent Ductus Arteriosus
Systemic Hypertension, Primary
Tetralogy of Fallot
Mitral Valve Disease
Atrioventricular Septal Defect, Complete
Transposition of the Great Arteries (D)
Kawasaki Disease
Patent Foramen Ovale
Supraventricular Tachycardia
Dilated Cardiomyopathy
Premature Ventricular Contractions
Atrioventricular Septal Defect, Partial
Hypoplastic Left Heart Syndrome
Hypertrophic Cardiomyopathy
Subaortic Stenosis
Aortopathy, Including Marfan
Pulmonary Atresia with Ventricular Septal Defect
Tricuspid Atresia
Tricuspid Valve Dysplasia, NonEbstein
Malalignment Ventricular Septal Defect, including
Double Outlet Right Ventricle
Venosus Defects and/or Partially Anomalous
Pulmonary Venous Connections
Total Anomalous Pulmonary Venous Connection
Double Inlet Single Ventricle
Premature Atrial Contractions
Subarterial Ventricular Septal Defect
Pulmonary Atresia Intact Ventricular Septum
Ebstein Anomaly
Pulmonary Arterial Branch Stenosis
Transposition of the Great Arteries (L)
Vascular Ring or Right Aortic Arch
Single Ventricle, Other
Supravalve Aortic Stenosis
Cardiac Tumor
Truncus Arteriosus
Pericardial Disease
Hyperlipidemia

479
366
318
268
226
155
131
116
99
96
81
68
64
63
57
53
47
41
31
31
30
29
28
21
20
22

127
87
78
62
64
52
27
31
23
14
21
17
15
15
14
11
15
12
13
8
8
5
5
9
8
4

606
453
396
330
290
207
158
147
122
110
102
85
79
78
71
64
62
53
44
39
38
34
33
30
28
26

17

8

25

21
19
15
18
14
15
14
14
15
12
9
11
11
10
9

3
3
7
3
5
4
4
4
1
3
6
3
2
2
2

24
22
22
21
19
19
18
18
16
15
15
14
13
12
11

The conditions listed above represent 3969 cases, or 96.6% of the sample. Another 65 (1.6%) have one of
the following primary diagnoses, and represented more than 5 times in the sample: anomalous coronary
arterial origin (6), atrioventricular block (10), coronary fistula (10), interrupted aortic arch (10), long QT
syndrome (6), myocarditis (7), primary pulmonary vascular obstructive disease (6), and Wolff-ParkinsonWhite electrocardiographic pattern without supraventricular tachycardia (10).

Table III.
Secondary Cardiac Diagnosis*

Number With
Derivation Cohort Validation Cohort Total

Patent Ductus Arteriosus
Aortic Valve Disease
Pulmonary Valve Disease
Secundum Atrial Septal Defect
Mitral Valve Disease
Muscular Ventricular Septal Defect
Patent Foramen Ovale
Perimembranous Ventricular Septal Defect
Supraventricular Tachycardia
Subpulmonary stenosis
Aortic Coarctation
Tricuspid Valve Dysplasia, NonEbstein
Pulmonary Arterial Branch Stenosis
Subaortic Stenosis
Malalignment Ventricular Septal Defect, including
Double Outlet Right Ventricle
Premature Ventricular Contractions
Aortopathy, Including Marfan
Arrhythmias, other
Transposition of the Great Arteries (D)
Dilated Cardiomyopathy
Venosus Defects and/or Partially Anomalous
Pulmonary Venous Connections
Atrioventricular Septal Defect, Complete
Coronary arterial anomalies, other

105
92
83
64
67
50
48
38
34
30
23
22
22
19
18

32
23
29
18
7
11
9
16
4
4
7
5
3
5
6

137
115
112
82
74
61
57
54
38
34
30
27
25
24
24

19
16
15
11
8
6

3
2
3
2
2
3

22
18
18
13
10
9

7
4

1
3

8
7

*Some patients have more than one secondary diagnosis.

FIGURE LEGENDS

Figure 1. Kaplan-Meier curves describing time associated freedom from invasive cardiovascular
intervention (A), and survival (B). No significant differences are identified between the
derivation and validation cohorts.

Figure 2. Validation and calibration of the freedom from invasive cardiovascular intervention
model at 4 months (A), 1 year (B), 5 years (C), 10 years (D) and 22 years (E).

Figure 3. Validation and calibration of the survival model at 4 months (A), 1 year (B), 5 years
(C), 10 years (D) and 22 years (E).

Figure 4. One way sensitivity analysis for factors associated with probability of survival (A) and
freedom from invasive cardiovascular intervention (B) at 22 years. Probability of event changes
much more with variation in diagnostic/pathophysiologic/prior intervention score than with
changes in any other model components. As mortality is much less common than intervention,
note the probability scales are different. Abbreviations: DPPIi/m = diagnosis, pathophysiologic,
prior intervention, intervention and mortality models, respectively. SECD i/m = secondary
diagnosis, intervention and mortality models, respectively.
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